Gilead внесет авансовый платеж в размере 1,25 млрд долларов компании ViiV Healthcare в первом квартале 2022 года.
gsk.com
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement
RSS Hunter
2022-02-01
Create attached notes ...